Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 1.88 USD 3.3% Market Closed
Market Cap: 410.2m USD
Have any thoughts about
Akebia Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one AKBA stock under the Base Case scenario is 2.51 USD. Compared to the current market price of 1.88 USD, Akebia Therapeutics Inc is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AKBA Intrinsic Value
2.51 USD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Akebia Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AKBA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AKBA?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Akebia Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Akebia Therapeutics Inc

Provide an overview of the primary business activities
of Akebia Therapeutics Inc.

What unique competitive advantages
does Akebia Therapeutics Inc hold over its rivals?

What risks and challenges
does Akebia Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Akebia Therapeutics Inc recently?

Summarize the latest earnings call
of Akebia Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Akebia Therapeutics Inc.

Provide P/S
for Akebia Therapeutics Inc.

Provide P/E
for Akebia Therapeutics Inc.

Provide P/OCF
for Akebia Therapeutics Inc.

Provide P/FCFE
for Akebia Therapeutics Inc.

Provide P/B
for Akebia Therapeutics Inc.

Provide EV/S
for Akebia Therapeutics Inc.

Provide EV/GP
for Akebia Therapeutics Inc.

Provide EV/EBITDA
for Akebia Therapeutics Inc.

Provide EV/EBIT
for Akebia Therapeutics Inc.

Provide EV/OCF
for Akebia Therapeutics Inc.

Provide EV/FCFF
for Akebia Therapeutics Inc.

Provide EV/IC
for Akebia Therapeutics Inc.

Show me price targets
for Akebia Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Akebia Therapeutics Inc?

How accurate were the past Revenue estimates
for Akebia Therapeutics Inc?

What are the Net Income projections
for Akebia Therapeutics Inc?

How accurate were the past Net Income estimates
for Akebia Therapeutics Inc?

What are the EPS projections
for Akebia Therapeutics Inc?

How accurate were the past EPS estimates
for Akebia Therapeutics Inc?

What are the EBIT projections
for Akebia Therapeutics Inc?

How accurate were the past EBIT estimates
for Akebia Therapeutics Inc?

Compare the revenue forecasts
for Akebia Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Akebia Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Akebia Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Akebia Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Akebia Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Akebia Therapeutics Inc with its peers.

Analyze the financial leverage
of Akebia Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Akebia Therapeutics Inc.

Provide ROE
for Akebia Therapeutics Inc.

Provide ROA
for Akebia Therapeutics Inc.

Provide ROIC
for Akebia Therapeutics Inc.

Provide ROCE
for Akebia Therapeutics Inc.

Provide Gross Margin
for Akebia Therapeutics Inc.

Provide Operating Margin
for Akebia Therapeutics Inc.

Provide Net Margin
for Akebia Therapeutics Inc.

Provide FCF Margin
for Akebia Therapeutics Inc.

Show all solvency ratios
for Akebia Therapeutics Inc.

Provide D/E Ratio
for Akebia Therapeutics Inc.

Provide D/A Ratio
for Akebia Therapeutics Inc.

Provide Interest Coverage Ratio
for Akebia Therapeutics Inc.

Provide Altman Z-Score Ratio
for Akebia Therapeutics Inc.

Provide Quick Ratio
for Akebia Therapeutics Inc.

Provide Current Ratio
for Akebia Therapeutics Inc.

Provide Cash Ratio
for Akebia Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Akebia Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Akebia Therapeutics Inc?

What is the current Free Cash Flow
of Akebia Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Akebia Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Akebia Therapeutics Inc

Current Assets 100.1m
Cash & Short-Term Investments 34m
Receivables 32.2m
Other Current Assets 33.9m
Non-Current Assets 107m
PP&E 11.8m
Intangibles 68.1m
Other Non-Current Assets 27.1m
Current Liabilities 65.7m
Accounts Payable 13.5m
Accrued Liabilities 52.2m
Non-Current Liabilities 191.8m
Long-Term Debt 38.4m
Other Non-Current Liabilities 153.5m
Efficiency

Earnings Waterfall
Akebia Therapeutics Inc

Revenue
169.9m USD
Cost of Revenue
-25.8m USD
Gross Profit
144m USD
Operating Expenses
-176.1m USD
Operating Income
-32m USD
Other Expenses
-14m USD
Net Income
-46m USD

Free Cash Flow Analysis
Akebia Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AKBA Profitability Score
Profitability Due Diligence

Akebia Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

32/100
Profitability
Score

Akebia Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

AKBA Solvency Score
Solvency Due Diligence

Akebia Therapeutics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
48/100
Solvency
Score

Akebia Therapeutics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AKBA Price Targets Summary
Akebia Therapeutics Inc

Wall Street analysts forecast AKBA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AKBA is 5.61 USD with a low forecast of 4.04 USD and a high forecast of 7.88 USD.

Lowest
Price Target
4.04 USD
115% Upside
Average
Price Target
5.61 USD
198% Upside
Highest
Price Target
7.88 USD
319% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AKBA?

Click here to dive deeper.

Dividends

Akebia Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AKBA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AKBA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

397.7m USD

Dividend Yield

0%

Description

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

Contact

MASSACHUSETTS
Cambridge
245 1st St
+16178712098.0
akebia.com

IPO

2014-03-20

Employees

426

Officers

CEO, President & Director
Mr. John P. Butler MBA
Senior VP of Research & Development and Chief Medical Officer
Dr. Steven Keith Burke M.D.
Senior VP, CFO & Chief Business Officer
Mr. Erik John Ostrowski M.B.A.
Chief Accounting Officer
Mr. Richard C. Malabre
Senior VP & Chief Technical Officer
Ms. Kimberly Garko
Vice President of Portfolio Strategy & Corporate Administration
Ms. Tracey Vetterick
Show More
Senior Director of Investor & Corporate Communications
Mercedes Carrasco
Senior VP of Legal, General Counsel & Secretary
Ms. Carolyn Rucci
Senior VP & Chief People Officer
Ms. Meredith Bowman
Senior VP & Chief Commercial Officer
Mr. Nicholas Grund
Show Less

See Also

Discover More
What is the Intrinsic Value of one AKBA stock?

The intrinsic value of one AKBA stock under the Base Case scenario is 2.51 USD.

Is AKBA stock undervalued or overvalued?

Compared to the current market price of 1.88 USD, Akebia Therapeutics Inc is Undervalued by 25%.

Back to Top